(Q37813687)

23 August 2017

1 reference

title

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo (English)

1 reference

23 August 2017

Awa Dicko

1

1 reference

23 August 2017

Lawrence D Mayer

series ordinal

2

1 reference

23 August 2017

Paul G Tardi

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Expert Opinion on Drug Delivery

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

12

1 reference

23 August 2017

1329-1341

1 reference

In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Optimizing combination chemotherapy by controlling drug ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Phase transitions in phospholipid vesicles Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

The function of sterols in membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

The role of surface charge and hydrophilic groups on liposome clearance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Chemical stability of liposomes: implications for their physical stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Stability of liposomal doxorubicin formulations: problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Spectroscopic studies on iron complexes of different anthracyclines in aprotic solvent systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Interactions of iron-anthracycline complexes with living cells: a microspectrofluorometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Effects of CPT-11 in combination with other anti-cancer agents in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Paclitaxel prodrugs: toward smarter delivery of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Biodegradable amphiphilic polymer-drug conjugate micelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Anticancer carrier-linked prodrugs in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2010.538678

10.1517/17425247.2010.538678

21 January 2018

Identifiers

DOI

1 reference

release_6aahqumoyjdjfgkqxdo52pgule

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6aahqumoyjdjfgkqxdo52pgule

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference